Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Clinical Cancer Research

Volumn 21, Issue 24, 2015, Pages 5469-5479

  Peeters, Marc ^a   Oliner, Kelly S ^b   Price, Timothy J ^c   Cervantes, Andrés ^d   Sobrero, Alberto F ^e   Ducreux, Michel ^f   Hotko, Yevhen ^g   André, Thierry ^h   Chan, Emily ⁱ   Lordick, Florian ^j   Punt, Cornelis J A ^k   Strickland, Andrew H ^l   Wilson, Gregory ^m   Ciuleanu, Tudor E ⁿ   Roman, Laslo ^o   Van Cutsem, Eric ^p   He, Pei ^b   Yu, Hua ^b   Koukakis, Reija ^b   Terwey, Jan Henrik ^b   Jung, Andre S ^b   Sidhu, Roger ^b   Patterson, Scott D ^b   more..

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b AMGEN INC   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UNIVERSITY OF GENOA   (Italy)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UZHGOROD NATIONAL UNIVERSITY   (Ukraine)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j Cancer Center Uniklinikum Leipzig   (Germany)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l MONASH MEDICAL CENTRE   (Australia)

^m CHRISTIE HOSPITAL   (United Kingdom)

ⁿ THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^o Leningrad Regional Oncology Dispensary   (Russian Federation)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAF GENE; CANCER SURVIVAL; CONSTIPATION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; EXON; FATIGUE; FEMALE; FEVER; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; ONCOGENE N RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARONYCHIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SKIN FISSURE; SKIN TOXICITY; STOMATITIS; VOMITING; WILD TYPE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DNA MUTATIONAL ANALYSIS; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; ONCOGENE RAS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84954163383     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0526     Document Type: Article

References (45)

1. Vectibix-(panitumumab). Full prescribing information. Thousand Oaks, CA: Amgen Inc.; 2014.
2. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995;1:19-31.
3. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: Proposal for an European quality assurance program. Virchows Arch 2008;453:417-31.
4. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 2013;3:112-23.
5. Wang Y, Velho S, Vakiani E, Peng S, Bass AJ, Chu GC, et al. Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov 2013;3: 294-307.
6. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
7. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28: 4697-705.
8. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
9. Van Cutsem E, K€ohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
10. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9.
11. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractorymetastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
12. Patterson SD, Peeters M, Siena S, Van Cutsem E, Humblet Y, Laethem JV, et al. Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). J Clin Oncol 2013;31:abstract 3617.
13. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19:1902-12.
14. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
15. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240-7.
16. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715-21.
17. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011;50:307-12.
18. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70:5901-11.
19. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006;5:928-32.
20. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). [cited Jun 2, 2014]. Available from: Http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
22. BransonM, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 2002;21:2449-63.
23. Law MG, Kaldor JM. Survival analyses of randomized clinical trials adjusted for patients who switch treatments. Stat Med 1996;15:2069-76.
24. Andre T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: A GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013;24:412-9.
25. Abad A, Massuti B, Gravalos C, Pilar E, Guillen C, Manzano JL, et al. Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study. J Clin Oncol 2014;32:abstract 3650.
26. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692-700.
27. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75.
28. Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial. Ann Oncol 2014;25:1756-61.
29. Bokemeyer C, Kohne C-H, Ciardiello F, Lenz H-J, Heinemann V, Klinkhardt U, et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 2014;32:abstract 3505.
30. Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahon MR, O'Neil BH, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or of oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC): Expanded RAS analyses. Ann Oncol 2014;25:abstract 5010.
31. Price TJ, Bruhn M, Lee C, Hardingham J, Townsend AR, Mann K, et al. Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC). J Clin Oncol 2014;32:abstract 3539.
32. Ciardiello F, Lenz H-J, Kohne C-H, Heinemann V, Tejpar S, Melezinek I, et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014;32: Abstract 3506.
33. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013;13:49.
34. NCCN clinical practice guidelines in oncology: Colon cancer v.3.2014. National Comprehensive Cancer Network. [cited Feb 11, 2014]. Available from: Http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf.
35. European Society of Pathology. Colon External Quality Assessment Scheme. [cited Jul 18, 2014]. Available from: Http://kras.eqascheme.org.
36. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3): Iii1-iii9.
37. Wong NA, Gonzalez D, Salto-Tellez M, Butler R, Diaz-Cano SJ, Ilyas M, et al. RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J Clin Pathol 2014;67:751-7.
38. Bendell JC, Atreya CE, Andr-e T, Tabernero J, Gordon MS, Bernards R, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 2014;32:abstract 3515.
39. Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 2014;32:abstract 3516.
40. Sotelo MJ, Garcia-Paredes B, Aguado C, Sastre J, Diaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014;20:4208-19.
41. PiessevauxH, Buyse M, SchlichtingM, Van Cutsem E, Bokemeyer C, Heeger S, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2013; 31:3764-75.
42. Mansmann UR, Sartorius U, Ruediger PL, Giessen CA, Esser R, Heinemann V. Deepness of response: A quantitative analysis of its impact on postprogression survival time after first-line treatment in patients with mCRC. J Clin Oncol 2013;31:abstract 427.
43. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14.
44. SeymourMT, Brown SR,Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. Lancet Oncol 2013;14:749-59.
45. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit inmetastatic colorectal cancer: Ameta-analysis of randomized controlled trials. Ann Oncol 2014;26:13-21.